A Research Guide for
Facing Cervical Cancer

A cervical cancer diagnosis is frightening, and nothing about the recent progress erases that. But it genuinely matters that you are facing this disease now rather than a decade ago, because almost every part of how it is treated has improved. For early-stage disease, we now know which operation gives the best chance of cure (and that the “smaller” keyhole approach was worse, a lesson learned and corrected). For locally advanced disease, adding the immunotherapy drug pembrolizumab to standard chemoradiation has improved cure rates in a landmark 2024 trial. And for advanced or recurrent disease, average survival has roughly tripled from where it stood ten years ago.

Three threads run through this progress. The first is immunotherapy — harnessing your own immune system — which has been woven into both curative and advanced treatment. The second is precision: better imaging and staging, image-guided radiation that hits the tumor while sparing healthy organs, and tumor testing that matches treatments to the patients most likely to benefit. The third is prevention: HPV vaccination is on track to make cervical cancer rare in coming generations, which fuels intense research interest in the disease.

None of this guarantees an easy road, and the right amount of hope depends on your individual situation, which your team can explain. But it is accurate and worth holding onto that cervical cancer is one of oncology's clearer success stories — a disease we are simultaneously getting better at preventing, detecting early, and treating at every stage.

PROVEN PREVENTION Gardasil 9 (Merck) is a 9-valent vaccine covering HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58. In clinical trials it demonstrated 97%+ efficacy against cervical precancers caused by the covered strains.

• Australia: Implemented school-based universal HPV vaccination in 2007 (girls) and 2013 (boys). By 2024, cervical cancer rates in vaccinated cohorts have fallen more than 90%. Australia is on track to be the first country to meet the WHO elimination threshold (<4 per 100,000 women).
• United Kingdom: A landmark 2021 analysis showed near-complete elimination of cervical cancer in women vaccinated before age 14. Rates of invasive cervical cancer dropped 87%; CIN3 dropped 97%.
• United States: Vaccination rates lag at approximately 60–65% of adolescents completing the full series, compared to 80–90%+ in Australia and the UK.
• HPV self-sampling: FDA-approved self-collection HPV tests (2024) allow women to collect their own vaginal swab at home for HPV primary screening, with sensitivity equivalent to clinician-collected samples.

FDA-APPROVED OCT 2021 KEYNOTE-826 (NCT03635567) added pembrolizumab to first-line chemotherapy ± bevacizumab for recurrent/metastatic cervical cancer.

• PD-L1 CPS ≥1 population: Median OS 28.6 vs 16.5 months (HR 0.60) — nearly 12 extra months of survival on average.
• All-comers: Benefit seen even in CPS <1. FDA approval covers all patients regardless of PD-L1 status.
• Practice change: Pembrolizumab + platinum-taxane ± bevacizumab is now the preferred first-line regimen for all eligible patients with recurrent/metastatic cervical cancer.

FDA-APPROVED JAN 2024 KEYNOTE-A18 (NCT04221945) is the first trial to add an immunotherapy to curative-intent chemoradiation and improve outcomes in locally advanced cervical cancer.

• Design: 1,060 patients; pembrolizumab 200 mg q3wks × 5 concurrent with chemoRT, then 400 mg q6wks × 15 maintenance cycles (~2 years total)
• PFS: HR 0.70 (p=0.002) — 30% reduction in risk of progression or death
• OS: HR 0.67 (p=0.004) at the second interim analysis (final-analysis HR 0.73) — significantly improved survival
• NCCN: Pembrolizumab + cisplatin/radiation is now Category 1 preferred for eligible patients with high-risk locally advanced cervical cancer

REGULAR FDA APPROVAL 2024 (innovaTV 301) Tisotumab vedotin (Tivdak, Seagen/Pfizer) targets tissue factor (TF), overexpressed on ~90% of cervical cancer cells, delivering MMAE cytotoxin directly to tumor cells.

• innovaTV 301 (NCT04697628): Median OS 11.5 vs 9.5 months (HR 0.70, p=0.0048) vs chemotherapy. Converted accelerated to full approval 2024.
• Mandatory eye care protocol: Cool compresses, steroid eye drops, vasoconstrictor drops on infusion day; ophthalmology every 6 weeks. No contact lenses during treatment. Failure to follow protocol risks permanent vision impairment.

PRACTICE-REVERSING The LACC trial (NCT00614211), NEJM 2018: 631 patients with FIGO IA1–IB1 randomized to open vs minimally invasive radical hysterectomy.

• DFS at 4.5 years: Open 97.1% vs MIS 91.2% (HR 3.74 for MIS — nearly 4x higher recurrence/death risk)
• OS: Open significantly better (HR 6.00 for MIS-related death)
• Current standard: Open (abdominal) radical hysterectomy is now the standard. MIS only considered for very small tumors (≤2 cm, no LVSI) at specialized centers with full informed consent.

The shift to MRI-guided adaptive brachytherapy (IGABT), formalized in the GEC-ESTRO EMBRACE studies, has dramatically improved outcomes while reducing toxicity. EMBRACE I outcomes (1,416 patients): 5-year local control exceeded 90% for stage IB–IIB and 85% for stage III–IVA. Brachytherapy omission significantly worsens outcomes and is not acceptable standard of care.

• Hispanic women: Highest cervical cancer incidence in the US (10.5 per 100,000 vs 7.2 overall). Driven by lower screening rates and inadequate access to follow-up.
• Black women: Highest cervical cancer mortality (3.8 per 100,000 vs 2.3 overall). When Black women receive the same stage-appropriate treatment as White women, outcomes are equivalent — proving the disparity is access-driven, not biology-driven.
• Globally: 85% of cervical cancer deaths occur in low- and middle-income countries. WHO 90-70-90 strategy targets elimination by 2030.

Cervical cancer is unusual among cancers in that we know its main cause — persistent infection with high-risk types of the human papillomavirus (HPV) — and we have tools that prevent the great majority of cases. The HPV vaccine (Gardasil 9) prevents roughly 90% of cervical cancers when given before exposure to the virus, which is why it is recommended routinely around ages 11–12 and can be given from age 9 through 26 (and, in some cases, to age 45 after discussion with a clinician). If you have children or grandchildren in that age range, vaccinating them is one of the most effective cancer-prevention steps available in all of medicine.

For adults, screening is the safety net that catches changes before they become cancer. The modern approach is HPV testing, which looks directly for the virus that causes nearly all cervical cancer and is more sensitive than the older Pap smear — so screening intervals can safely be longer (every five years for primary HPV testing in most women aged 25–65). Importantly, an abnormal screen is not cancer: most abnormalities are precancerous changes that can be removed with a minor office procedure, preventing cancer entirely.

A newer development puts screening more directly in your hands: self-collection HPV testing, FDA-approved in 2024, lets you collect your own sample (in a clinic or, increasingly, at home) with sensitivity comparable to a clinician-collected sample. For anyone who has avoided screening because of discomfort, lack of time, past trauma, or access barriers, this is a meaningful new option — and a reason to ask your clinician whether it is available to you. The bottom line: between vaccination and screening, cervical cancer is largely preventable, and staying up to date on both is the single most powerful thing you can do.

• HPV primary screening alone (every 5 years): Preferred strategy per ACS 2020 and USPSTF 2018 for women age 25–65. A negative high-risk HPV test is a stronger negative predictor than a negative Pap smear.
• HPV + Pap co-testing (every 5 years): Acceptable alternative for ages 30–65.
• Pap alone (every 3 years): Acceptable when HPV testing is unavailable or refused.
• Result interpretation:
  • HPV negative, Pap NILM → return to routine screening (5 years)
  • HPV 16 or 18 positive → colposcopy regardless of Pap result
  • HPV positive (not 16/18), Pap NILM → 1-year follow-up co-testing
  • HSIL Pap → immediate colposcopy regardless of HPV result
  • AGC Pap → colposcopy + endocervical curettage + endometrial sampling if indicated

FDA cleared the Teal Wand (Teal Health) self-collection device in 2024 for use with the Roche cobas HPV assay. Self-collected vaginal swabs achieve equivalent HPV detection rates to clinician-collected samples. Most important for transgender men, women with dysphoria related to pelvic exams, and rural/remote populations. Note: self-sampling detects HPV but does not include cytology — positive results still require clinic-based follow-up.

• Women aged 21–24: Pap smear only every 3 years. HPV testing not recommended (near-universal transient HPV would generate massive overreferral).
• HIV-positive women: Annual Pap smear for 3 consecutive years from HIV diagnosis (regardless of age), then every 3 years if all normal. CD4 <200 or active AIDS: some guidelines recommend continuing annual screening indefinitely.
• After hysterectomy with cervix removed: No cervical screening needed if no history of CIN2+ or cervical cancer in prior 25 years.
• Pregnancy: Screening continues per standard intervals. Colposcopy is safe. ECC is contraindicated. Brachytherapy absolutely contraindicated.
• Transgender men with a retained cervix: Same screening schedule as cisgender women. Testosterone may cause atrophic changes that complicate Pap interpretation — inform the pathologist. Self-sampling is especially preferred.
• HPV vaccination does not change screening intervals — even fully vaccinated women need regular cervical screening.

Colposcopy: Magnified examination of the cervix after acetic acid application; biopsies taken from abnormal areas. ECC samples the endocervical canal. Sensation: brief pinch and cramping from biopsies; manageable with NSAIDs 1 hour before.

LEEP: Loop electrosurgical excision; outpatient under local anesthetic. Provides both treatment and a pathology specimen for margin assessment.

Cold Knife Conization (CKC): Preferred when margin assessment is critical (AIS, suspicion of invasive cancer, deep endocervical extension, or LEEP technically difficult). Performed in OR under anesthesia; cleaner specimen margins.

Post-LEEP surveillance: Co-testing (HPV + Pap) at 6, 12, and 24 months. If all normal, return to 5-year routine screening.

1. Am I using the right screening interval for my age and health history?
2. Should I have HPV primary testing, co-testing, or Pap alone?
3. My HPV test was positive for HPV 16 or 18 — what does that mean for my risk?
4. I’m HIV-positive — what screening schedule should I be on?
5. I’m pregnant and have an abnormal result — what can safely be done during pregnancy?
6. My doctor recommended LEEP — will it affect my ability to get pregnant in the future?
7. Is self-sampling HPV testing available as an option for me?

Staging can feel like an intimidating string of numbers and letters, but its real purpose is simple: it sorts cervical cancer into groups that are treated in fundamentally different ways, so knowing roughly where you fall tells you what kind of plan to expect. The single biggest divide is between cancer confined to a small area of the cervix, which is usually treated with surgery, and cancer that has grown larger or spread beyond the cervix, which is usually treated with chemoradiation rather than an operation. A guiding principle your team follows is to use one definitive treatment, not both, because combining major surgery with radiation adds a lot of long-term side effects without improving the chance of cure.

The 2018 staging update added an important refinement that explains why imaging matters so much now: whether the cancer has reached nearby lymph nodes is part of the stage. Nodes can harbor cancer that a physical exam cannot detect, so an MRI and a PET-CT are done to find it — and a tumor that looks small locally may still be treated as more advanced if the scans show node involvement. This is why your stage may rest on imaging results rather than just the exam, and why those scans are worth the wait.

What this means for you as a patient: ask your team to explain your stage in plain terms and, more usefully, what pathway it puts you on — surgery, chemoradiation, or systemic therapy — and why. Understanding the logic (small and contained → surgery; larger or node-positive → chemoradiation with brachytherapy; spread to distant sites → drug therapy) turns a confusing label into a roadmap you can follow and ask questions about.

• MRI pelvis (with and without contrast): Best imaging for local staging. Defines tumor size, parametrial invasion, vaginal involvement, and relationship to bladder and rectum. Required for all patients before surgery or chemoradiation planning.
• PET-CT (18F-FDG whole body): Preferred staging tool for lymph node and distant metastases. Detects para-aortic node involvement in 15–30% of patients thought to be pelvic-only disease on CT. Changes management in ~20–30% of locally advanced cases.
• Cystoscopy: Required if MRI suggests bladder involvement. Confirms IVA staging.
• Proctoscopy/sigmoidoscopy: Required if MRI suggests rectal involvement.
• Renal function: Serum creatinine before cisplatin. Hydronephrosis must be managed before initiating cisplatin.
• Biomarker testing: PD-L1 CPS (22C3 assay), MMR/MSI status, NTRK fusion should be ordered at diagnosis for any locally advanced or recurrent disease.

1. What is my exact FIGO 2018 stage, including the substage letter (e.g., IIIC1r vs IIIC1p)?
2. Has PET-CT been done? Did it change the stage compared to MRI alone?
3. Is there any hydronephrosis? Does the kidney need a stent before chemotherapy?
4. Has PD-L1 CPS testing been ordered? What is the score?
5. Has MMR/MSI testing been done?
6. Will my radiation field need to cover para-aortic nodes?
7. Is fertility-preserving surgery still an option given my stage?

Because cervical cancer is often diagnosed in younger women, one of the most pressing questions is whether treatment will end the chance of having children — and for early-stage disease, the answer is increasingly “not necessarily.” The key point is that fertility-preserving options exist but must be discussed before any treatment begins, because the standard treatments (removing the uterus, or radiation to the pelvis) permanently end fertility once they are done. This is a conversation to start at the very first appointment, and a reason to ask specifically for referral to a gynecologic oncologist and, where relevant, a fertility specialist.

For the smallest, earliest cancers, a cone biopsy (removing just a cone-shaped piece of the cervix) may be enough and leaves the uterus intact. For somewhat larger early tumors (generally up to 2 cm), an operation called a radical trachelectomy removes the cervix and surrounding tissue while keeping the uterus, so that pregnancy remains possible — and in carefully selected patients the cancer outcomes are comparable to removing the whole uterus. Pregnancies after trachelectomy are possible but considered higher-risk and need specialist care.

If your treatment will involve chemotherapy or radiation rather than fertility-sparing surgery, there are still options to discuss before starting: freezing eggs or embryos preserves the possibility of a biological child (carried by a surrogate if the uterus is treated), and an operation to move the ovaries out of the radiation field (ovarian transposition) can help protect hormone function. None of these are guaranteed, and they are time-sensitive — but they are real, and the worst outcome is not knowing they existed. Whatever your situation, ask early and ask directly.

Standard pelvic lymphadenectomy: Systematic removal of bilateral pelvic lymph nodes (external iliac, internal iliac, obturator, common iliac, presacral). Removes 20–35 nodes per side.

Sentinel lymph node (SLN) biopsy (tumors ≤2 cm): ICG injected into the cervix at 3 and 9 o’clock positions; fluoresces under near-infrared light. Bilateral detection required — if only unilateral detection, complete ipsilateral full lymphadenectomy. Ultrastaging of SLN detects micrometastases (>0.2 mm) and isolated tumor cells (≤0.2 mm). SENTICOL and SENTIX trials validated this approach. Lymphedema risk reduction: full lymphadenectomy causes lymphedema in 15–25% vs substantially less with SLN.

Removes the cervix, parametrium, and upper vagina while leaving the uterine body intact. A permanent cerclage is placed at the internal os. Pregnancy is possible afterward.

Strict selection criteria: Strong desire for future fertility; FIGO stage IA2 or IB1; tumor ≤2 cm; no lymph node metastases (SLN biopsy first); squamous cell carcinoma or usual-type adenocarcinoma (not gastric-type, not neuroendocrine); no LVSI (relative contraindication); tumor not extending close to internal os (need ≥5–10 mm clear margin).

Obstetric outcomes: Conception rates ~55–70% among women who attempt pregnancy. All pregnancies managed as high-risk; delivery by elective cesarean at 34–36 weeks.

Ovarian preservation: SCC has <1% risk of ovarian metastases — ovaries can safely be preserved. Adenocarcinoma carries ~2–5% risk — shared decision-making required. Ovarian transposition (oophoropexy) before radiation relocates ovaries outside the radiation field to preserve hormonal function; success rate 50–80%.

The most radical surgical procedure in gynecologic oncology — performed for central pelvic recurrence after prior radiation when systemic therapy offers no curative potential.

• Types: Anterior (removes uterus, vagina, bladder — urinary diversion required); Posterior (removes uterus, vagina, rectum — colostomy required); Total (removes all three — both diversions required).
• 5-year OS: ~40–60% in carefully selected patients (small recurrence, R0 margins, longer disease-free interval, no pelvic sidewall involvement, no distant metastases).
• Should only be performed at high-volume centers by surgeons who perform >5–10 exenterations per year.

High-risk features (Peters criteria) — adjuvant concurrent chemoradiation: Positive surgical margins; positive pelvic lymph nodes; parametrial involvement. Any one of these three criteria is sufficient to recommend adjuvant chemoradiation (cisplatin + pelvic RT).

Intermediate-risk features (Sedlis criteria) — adjuvant pelvic radiation only:

Critical principle — avoid double treatment: Patients who receive radical surgery followed by full-course concurrent chemoradiation have dramatically higher complication rates (fistula, bowel obstruction, lymphedema, bladder dysfunction). When possible, select patients for one modality only. If parametrial involvement is suspected on MRI (suggesting IIB), primary chemoradiation is preferred.

1. Is open surgery being recommended based on the LACC trial findings? If minimally invasive is proposed, why?
2. What Querleu-Morrow type is planned (B, C1, or C2)? Will the pelvic nerve plexus be preserved?
3. Will sentinel lymph node biopsy be attempted, or full pelvic lymphadenectomy?
4. Am I a candidate for fertility-sparing radical trachelectomy? What are the exact criteria?
5. Can my ovaries be preserved? Should I have ovarian transposition before radiation?
6. What pathologic findings after surgery would trigger adjuvant treatment?
7. How many radical hysterectomies does this team perform per year?
8. If I require adjuvant radiation after surgery, what are the combined long-term complication risks?

• Open surgery means a longer recovery. Plan for a 4–6 day hospital stay and 6–8 week recovery at home. The survival benefit is worth the longer recovery.
• Post-surgery bladder care: Some women are discharged with a Foley catheter or need intermittent self-catheterization while bladder function recovers. This is manageable with practical instruction.
• Fertility grief: If surgery removes any possibility of future pregnancy, grief counseling and peer support networks are invaluable.
• For pelvic exenteration: The patient will live with an ostomy bag for urine and/or feces. Stoma nurse education before and after surgery is essential. CancerCare (1-800-813-4673) offers support groups for GYN cancer survivors with ostomies.

For locally advanced cervical cancer, chemoradiation is given with the goal of cure, not just control — an important thing to hold onto, because the treatment is demanding. It has three parts working together: daily external radiation (Monday through Friday for about five weeks), a low dose of chemotherapy (usually cisplatin) once a week to make the radiation work better, and — critically — a course of internal radiation called brachytherapy at the end. Brachytherapy places the radiation source right at the tumor and is the part that most determines whether the cancer is cured; it is not optional, and a center that treats cervical cancer should offer it (if yours does not, ask to be referred).

One fact is worth understanding because you can help protect it: the total treatment should be completed within about 7–8 weeks. Stretching it out — through missed appointments, avoidable delays, or postponed brachytherapy — gives the cancer time to regrow and measurably lowers the chance of cure. So keeping appointments and finishing on schedule is genuinely part of the treatment. If side effects are making that hard, tell your team rather than skipping sessions; they can almost always help you push through.

Side effects build over the weeks and commonly include diarrhea, fatigue, bladder irritation, and lowered blood counts; most are managed with supportive medicines and ease after treatment ends. Two longer-term effects deserve early attention: vaginal narrowing (stenosis), which regular use of a vaginal dilator after treatment largely prevents and which protects both comfort and future exams, and, in younger women, menopause if the ovaries were in the radiation field. Ask your team about a dilator and about hormone options — these conversations are a normal part of good care, even if they feel awkward to raise.

• Standard dose: 45–50.4 Gy in 25–28 daily fractions over ~5 weeks (Mon–Fri). Each treatment session takes 10–20 minutes.
• Extended-field radiation: When para-aortic nodes are involved (FIGO IIIC2), the field is extended superiorly to cover the para-aortic region up to L1–L2.
• IMRT (Intensity-Modulated Radiation Therapy): The modern standard. Multiple randomized and prospective studies confirm IMRT reduces grade 3+ GI and GU toxicity by 30–50% compared to 3D-CRT without compromising tumor control. IMRT is strongly preferred at experienced centers (NCCN and ESGO recommended).
• Hydronephrosis management: Stage IIIB disease often causes ureteral obstruction. A ureteral stent or percutaneous nephrostomy tube may be required before starting cisplatin to protect kidney function.

• Cisplatin 40 mg/m² weekly: Standard concurrent chemotherapy given for 5–6 weekly doses during EBRT. Pre-hydration (1–2 L IV fluid) required. This is specifically the radiosensitizer dose — not a reduced dose.
• Carboplatin substitution (AUC 2 weekly): For patients who cannot receive cisplatin due to renal impairment (CrCl <50 mL/min), pre-existing neuropathy, hearing loss, or prior hypersensitivity. Considered acceptable but not equivalent in efficacy to cisplatin. Cisplatin is strongly preferred when safely tolerable.
• No second chemotherapy drug: Multiple trials have tested adding a second agent (gemcitabine, paclitaxel, 5-FU) — generally negative or inconclusive, with more toxicity but not improved efficacy. Cisplatin alone remains the standard.
• Monitoring: Weekly CBC and basic metabolic panel before each dose. Magnesium supplementation commonly required (cisplatin causes magnesium wasting).

Brachytherapy is not optional. Multiple studies confirm that omitting brachytherapy (substituting an external beam boost) significantly worsens local control and survival. The physics reason: brachytherapy delivers extremely high dose directly to the cervix and uterus, with rapid dose falloff that spares rectum, bladder, and bowel.

• Timing: Begins in the last 1–2 weeks of EBRT or immediately after. Goal: complete all brachytherapy within the 7–8 week overall treatment window.
• Sessions: Typically 4–5 HDR fractions, each ~5.5–7 Gy, separated by at least 6 hours.
• Applicators: Tandem (through cervix into uterus) + ring or ovoids (alongside cervix). Placed under anesthesia or sedation. Total time per session: 2–5 hours (placement, imaging, planning, delivery).
• Image-Guided Adaptive Brachytherapy (IGABT): Gold standard. MRI (or CT) performed with applicator in place allows dose optimization to the HR-CTV (high-risk clinical target volume) while keeping bladder, rectum, and sigmoid below tolerance. EMBRACE I registry data demonstrate dramatically lower local recurrence and late toxicity vs older point-based methods. Ask specifically whether your center performs MRI-guided or CT-guided brachytherapy.
• HR-CTV D90 dose target: At least 85 Gy EQD2 to 90% of the HR-CTV. Larger tumors often require 90–95+ Gy EQD2 for adequate control.
• Combined intracavitary-interstitial (IC-IS) brachytherapy: For tumors with significant parametrial extension, interstitial needles are added through the perineum. Allows dose delivery to lateral parametrial disease that standard intracavitary applicators cannot adequately cover.

FDA-APPROVED JAN 2024 — CATEGORY 1 NCCN

• Design: 1,060 patients; FIGO 2014 stage IB2–IIB with pelvic LN involvement or stage III–IVA; pembrolizumab 200 mg q3wks × 5 concurrent with chemoRT, then 400 mg q6wks × 15 maintenance doses (~2 years total) vs placebo.
• Results: PFS HR 0.70 (p=0.002); OS HR 0.67 (p=0.004; final-analysis HR 0.73). Greatest benefit in FIGO III–IVA.
• PD-L1 testing for this indication: Not required. Benefit observed across all-comers regardless of CPS, likely because radiation upregulates PD-L1 and enhances immune response.
• CALLA trial (durvalumab) — NEGATIVE: The CALLA trial (NCT03830866) tested durvalumab (anti-PD-L1) + chemoRT and was negative (HR 0.84, p=0.07). Anti-PD-1 (pembrolizumab) and anti-PD-L1 (durvalumab) are not interchangeable. Only pembrolizumab has FDA approval for concurrent use with chemoRT for locally advanced cervical cancer.

Acute (during treatment and up to 3 months after):

• Diarrhea and bowel cramping: Most common. Begins weeks 2–3. Management: low-residue diet, loperamide, diphenoxylate-atropine. IMRT significantly reduces severity vs older techniques.
• Urinary symptoms: Frequency, urgency, burning. Management: hydration, urinary analgesics, avoid caffeine and alcohol.
• Fatigue: Near-universal and cumulative. Gentle walking 20–30 min daily reduces radiation-associated fatigue.
• Anemia: Very common. Hemoglobin target ≥10 g/dL during radiation recommended (oxygen is needed for radiation-induced DNA damage). Transfusion may be required.
• Nausea: Prophylactic antiemetics (ondansetron, prochlorperazine) given with cisplatin.

Late (months to years after completion):

• Vaginal stenosis: Very common — affects the majority of women treated with pelvic radiation + brachytherapy. Prevention: vaginal dilators 3×/week beginning 2–3 weeks after completing brachytherapy, continuing for 2+ years. Without dilator use, stenosis can progress until pelvic examination becomes impossible (critical for cancer surveillance).
• Premature menopause: Inevitable in premenopausal women unless ovaries were transposed. HRT is recommended and considered safe for cervical cancer (not hormone-driven).
• Bowel complications: Late radiation proctitis, small bowel obstruction, fistula. Fistulas (rectovaginal, vesicovaginal) occur in 1–5% — risk higher with combined surgery+radiation, bevacizumab use, and central pelvic disease.
• Lymphedema: Risk substantially higher when both radical surgery with lymphadenectomy and full-course radiation are performed.
• Bone health: Premature menopause + pelvic radiation increases insufficiency fracture risk (sacral, pubic rami). DEXA scan, calcium+Vitamin D supplementation, weight-bearing exercise, bisphosphonate therapy if osteoporosis develops.

• Vaginal dilator use: Begin 2–3 weeks after completing brachytherapy. 10–15 minutes, 3×/week. Graduated sizes. This is a medical procedure for tissue preservation, not a sexual act. A pelvic floor PT can teach proper technique.
• Topical vaginal estrogen: Considered safe after cervical cancer. Often more effective at restoring vaginal tissue health than systemic estrogen alone.
• Pelvic floor physical therapy: Addresses vaginismus, pelvic pain, bladder urgency, and bowel dysfunction. Referral should be routine after pelvic radiation or radical hysterectomy.
• When to resume sexual activity: Most radiation oncologists recommend waiting 2–3 weeks after completing brachytherapy to allow acute mucositis to heal. Resuming sexual activity when comfortable is encouraged — regular intercourse also helps prevent vaginal stenosis.

• Am I eligible for pembrolizumab added to my chemoradiation based on KEYNOTE-A18?
• Will I receive IMRT or 3D-CRT? If 3D-CRT, can I be referred to an IMRT center?
• Will I receive image-guided adaptive brachytherapy? Is MRI-guided brachytherapy available here?
• How many brachytherapy sessions will I need, and how long does each take?
• Will I need extended-field radiation to cover para-aortic nodes? What does that mean for side effects?
• Do I have hydronephrosis? Do I need a ureteral stent before starting?
• Will I receive cisplatin or carboplatin, and why?
• When should I start vaginal dilators after brachytherapy is complete?
• Is there a pelvic floor physical therapist at this center who sees cancer patients?
• What symptoms should prompt me to call immediately (signs of fistula, etc.)?

• Daily transportation is real work. 25–28 daily appointments over 5+ weeks plus 4–5 brachytherapy sessions. Help with reliable transportation is one of the most practical contributions. Ask the social worker about American Cancer Society Road to Recovery or local programs if driving is not possible.
• Fatigue builds in the last 2 weeks. Plan for increased help with meals, household tasks, and personal care during the final stretch. This is normal, expected, and temporary.
• The HPV conversation: Partners may feel guilt or blame. Reassure everyone that HPV is extraordinarily common — cervical cancer reflects an unlucky intersection of HPV persistence, immune factors, and lack of screening, not anyone’s fault.
• Sexual health is a shared journey. Approach the dilator protocol and gradual resumption of intimacy as a team effort.

If cervical cancer has spread or come back, it is natural to fear that little can be done — but this is one of the areas where the outlook has genuinely improved in the last few years, and the numbers are worth knowing. A decade ago, average survival for advanced cervical cancer was roughly 10–11 months. With today's standard first-line treatment — chemotherapy combined with bevacizumab (which starves the tumor's blood supply) and the immunotherapy drug pembrolizumab — average survival for the majority of patients has risen to nearly 29 months, and a meaningful number do considerably better than average. This is real, hard-won progress.

Pembrolizumab works differently from chemotherapy: rather than poisoning dividing cells, it releases a brake on your own immune system so it can recognize and attack the cancer. It helps most patients because about 85–90% of cervical cancers carry a marker (called PD-L1) that predicts benefit — which is why your team will test for it. Because immunotherapy revs up the immune system, its side effects are different from chemotherapy's: it can occasionally cause the immune system to attack normal organs (the thyroid, skin, gut, liver, or lungs), so report new symptoms promptly, as these are very treatable when caught early.

Two practical points help you be an active partner. First, ask whether your tumor has been tested for PD-L1, since it guides the best first-line choice. Second, ask about clinical trials at every stage — advanced cervical cancer is an area of active research (including HPV-targeted vaccines and new antibody-drug treatments), and a trial is often a good option rather than a last resort. Alongside treatment, palliative care (specialists in symptom control and quality of life) can help you feel better and is appropriate from the start, not only at the end.

FDA-APPROVED OCT 2021

KEYNOTE-826 (NCT03635567): 617 patients with persistent, recurrent, or first-line metastatic cervical cancer randomized to pembrolizumab + chemotherapy (cisplatin 50 mg/m² or carboplatin AUC5 + paclitaxel 175 mg/m² q3wks) ± bevacizumab 15 mg/kg vs placebo + same chemotherapy.

PD-L1 CPS ≥1 (88% of trial):

• Median OS: 28.6 months vs 16.5 months (HR 0.60, p<0.001)
• Median PFS: 10.4 vs 8.2 months (HR 0.62, p<0.001)
• ORR: 68% vs 50%

All-comers: Median OS 24.4 vs 16.5 months (HR 0.67). Benefit seen regardless of whether bevacizumab was included.

Current standard first-line regimen:

• Pembrolizumab 200 mg IV q3wks (flat dose)
• Cisplatin 50 mg/m² d1 or carboplatin AUC 5 d1 q3wks × 6 cycles
• Paclitaxel 175 mg/m² d1 q3wks × 6 cycles (premedication with dexamethasone, diphenhydramine, H2-blocker required)
• Bevacizumab 15 mg/kg IV q3wks (when risk-benefit assessment favors inclusion)
• After 6 cycles of platinum/paclitaxel, pembrolizumab (and bevacizumab if included) continues until disease progression, unacceptable toxicity, or 24 months total pembrolizumab

Cisplatin vs carboplatin: Cisplatin 50 mg/m² q3wks is preferred. Carboplatin AUC 5 is substituted for renal impairment (CrCl <50–60 mL/min), significant pre-existing neuropathy, prior cisplatin hearing loss, or prior sensitization. Most patients have already received cisplatin during chemoRT — cumulative platinum toxicity (especially neuropathy) is a consideration.

FDA-APPROVED 2014

GOG 240 (NCT00803062): Adding bevacizumab improved median OS from 13.3 to 17.0 months (HR 0.71, p=0.004). First biologic to improve overall survival in cervical cancer.

Fistula risk: The most critical safety concern. In GOG 240, fistula rate was ~6% with bevacizumab vs 1% without. Fistulas — vesicovaginal (urine leaking through vagina) or rectovaginal (stool leaking through vagina) — are serious and often irreparable.

Risk factors for fistula: Prior pelvic radiation (present in nearly all recurrent cervical cancer patients); combined prior surgery+radiation; central pelvic disease; active infection; prior bowel surgery in the pelvis.

Despite the fistula risk, the OS benefit makes bevacizumab appropriate for most patients. Omission is considered in patients with very high fistula risk. This is an individualized decision requiring frank discussion.

Bevacizumab side effects: Hypertension (very common — monitor at each visit); proteinuria (dipstick or 24-hr urine monitoring; hold if ≥2 g/24 hrs); impaired wound healing (hold 4 weeks before/after major surgery); GI perforation (rare but serious given prior radiation bowel damage); arterial thromboembolism.

• MSI-H / dMMR (~1–3%): FDA tumor-agnostic approval for pembrolizumab (KEYNOTE-158) regardless of CPS or prior lines. MMR testing by IHC (MLH1, MSH2, MSH6, PMS2) should be performed on all recurrent cases.
• NTRK gene fusions (<1%): Actionable with larotrectinib (Vitrakvi) or entrectinib (Rozlytrek), both FDA-approved tumor-agnostically. Include NTRK testing in comprehensive NGS panels.
• TMB-high (≥10 mut/Mb): Pembrolizumab tumor-agnostic approval (FDA). Measured by comprehensive genomic profiling (Foundation One CDx or equivalent).
• HER2: HER2 overexpression/amplification occurs in a minority, particularly adenocarcinomas. Emerging area — trials evaluating HER2-targeting agents ongoing. No established standard-of-care agents yet.
• Comprehensive NGS panel recommendation: All recurrent/metastatic cervical cancer patients should have comprehensive genomic profiling (Foundation One, Tempus, Guardant, or similar CLIA-certified platform) to identify rare actionable alterations and guide clinical trial matching.

• Has PD-L1 CPS testing been performed using the Dako 22C3 assay? What is my score?
• Am I eligible for pembrolizumab added to chemotherapy (KEYNOTE-826)?
• Will bevacizumab be included? What is my risk of developing a fistula?
• Will I receive cisplatin or carboplatin, and why?
• Has comprehensive genomic profiling (NGS) been ordered?
• Is there a clinical trial open for first-line recurrent/metastatic cervical cancer?
• What symptoms of immune-related side effects from pembrolizumab should prompt me to call?
• Will I see a palliative care specialist to help manage symptoms during treatment?
• Is my case being discussed at a multidisciplinary tumor board?

If cervical cancer grows despite first-line treatment, it is a hard moment — but there are still active options, and understanding them helps you make informed choices. The most important newer drug in this setting is tisotumab vedotin, a type of treatment called an antibody-drug conjugate: it works like a guided missile, using an antibody to deliver a cell-killing payload directly to tumor cells. It improved survival compared with chemotherapy in its key trial and is FDA-approved for cervical cancer that has progressed. It has one distinctive requirement — a specific routine to protect your eyes (a cooling mask and eye drops around each infusion) — which is built into how it is given.

Other options depend on what you have already received. If you did not have immunotherapy in the first line, a checkpoint inhibitor (cemiplimab, where available) may be used. If targeted options are exhausted or not tolerated, several single-agent chemotherapies can still provide benefit. None of these is a cure in this setting, and response rates are modest, so the goals shift toward extending good-quality time and controlling symptoms.

This is the setting where clinical trials deserve the most serious consideration — not as a desperate last resort, but because the standard later-line options are limited and trials offer access to genuinely new approaches (HPV-targeted treatments, new antibody-drug conjugates, immunotherapy combinations). Ask your team to screen you for trials at this point. And it is entirely appropriate — advisable, in fact — to involve palliative care alongside cancer treatment here; these specialists are experts in helping you feel as well as possible, and using them is associated with both better quality of life and, in some studies, longer survival.

EU (EMA NOV 2022) & CANADA (2022) APPROVED — NOT FDA-APPROVED FOR CERVICAL CANCER

Cemiplimab is FDA-approved for skin cancers (cutaneous squamous cell, basal cell) and non-small cell lung cancer, but the FDA has not approved it for cervical cancer. It is approved for recurrent/metastatic cervical cancer in the European Union and Canada, and is included in some treatment guidelines based on the EMPOWER-Cervical 1 results below.

EMPOWER-Cervical 1 (NCT03257267): 608 patients with recurrent/metastatic cervical cancer progressing on/after platinum-based chemotherapy. Cemiplimab 350 mg IV q3wks vs investigator’s choice single-agent chemotherapy.

• Median OS: 12.0 months vs 8.5 months (HR 0.69, p<0.001)
• ORR: 16.4% vs 6.3%
• PD-L1 agnostic: Benefit regardless of PD-L1 status — no biomarker required
• Both histologies: Benefit in SCC and adenocarcinoma

Role today: With pembrolizumab now standard in first line, cemiplimab in second line after prior anti-PD-1 therapy has limited benefit due to overlapping mechanisms. Most relevant for patients who did not receive pembrolizumab in first line.

Tisotumab vedotin (TV, Tivdak, Seagen/Pfizer) is an ADC: anti-TF antibody conjugated via protease-cleavable linker to MMAE (microtubule-disrupting agent). When the antibody binds TF on cervical cancer cells, the ADC is internalized, MMAE is released inside the cell, causing death.

innovaTV 204 (NCT03438396) — accelerated approval basis: Single-arm Phase 2, 101 patients, 2L+ recurrent/metastatic. ORR 24%, complete responses 7%, median DOR 8.3 months.

innovaTV 301 (NCT04697628) — confirmatory Phase 3: 502 patients; TV vs investigator’s choice chemotherapy in 2L+ after platinum and anti-PD-1/PD-L1 therapy.

• Median OS: 11.5 months (TV) vs 9.5 months (chemo), HR 0.70 (p=0.0038)
• ORR: 17.8% vs 5.2%
• Full FDA approval confirmed based on this confirmatory trial

Eligibility: Patients with recurrent/metastatic cervical cancer previously treated with platinum-based chemotherapy and anti-PD-1/PD-L1 immunotherapy. TF expression testing not required (approved regardless of TF level).

Pre-infusion protocol (within 30–60 minutes BEFORE EACH DOSE):

1. Cool sterile saline compresses: Apply to closed eyelids for 10 minutes immediately before infusion.
2. Vasoconstrictive eye drops: 1 drop tetrahydrozoline (Visine) or naphazoline into each eye within 30 minutes before infusion.
3. Ophthalmic corticosteroid drops: 2 drops 1% prednisolone acetate ophthalmic suspension into each eye beginning the day before each infusion and continuing for 2 days after (3 days total, QID = 4x/day).
4. Lubricating eye drops: Preservative-free artificial tears at least 4x/day throughout treatment; lubricating ophthalmic gel or ointment at night.
5. Contact lenses: AVOID throughout entire course of TV treatment.

Ophthalmology monitoring: Baseline slit-lamp exam before starting; every 6 weeks during treatment; 4 weeks after completing or discontinuing. Any new eye symptoms (redness, pain, blurry vision, tearing, photophobia): urgent evaluation within 24–48 hours.

Other significant TV toxicities: Alopecia (near-universal), peripheral neuropathy (dose reduce at grade 2+; discontinue at grade 3+), epistaxis/bleeding (TF expressed in nasal epithelium), fatigue. TV can cause fetal harm — effective contraception mandatory.

• Topotecan: 1.0–1.5 mg/m² days 1–5 q3wks (IV) or oral. Significant myelosuppression. G-CSF support may be required.
• Weekly paclitaxel: 80 mg/m² IV weekly (3 weeks on, 1 off). Peripheral neuropathy (cumulative), alopecia, fatigue.
• Gemcitabine: 800–1000 mg/m² days 1, 8. Myelosuppression and fatigue.
• Vinorelbine: 25–30 mg/m² IV weekly. Peripheral neuropathy, constipation, myelosuppression.
• Irinotecan: 125 mg/m² weekly ×4 q6wks. Characteristic delayed diarrhea (>24 hours after infusion) — manage with early loperamide.
• Pemetrexed: 500 mg/m² q3wks with vitamin B12 and folic acid supplementation. Modest activity; well-tolerated.

At ECOG PS 2, single-agent therapy preferred over combinations. At ECOG PS 3–4, best supportive care and palliative care consultation should be primary focus.

innovaTV 205 early data showed ORR ~45% for tisotumab vedotin + pembrolizumab — substantially higher than either agent alone. Not yet FDA-approved. Rationale: ADC-induced tumor cell death releases neoantigens that enhance immune response, potentially synergizing with checkpoint inhibition. Phase 3 confirmatory data awaited. Ask about clinical trial availability.

The treatment landscape beyond pembrolizumab + chemo + bev and tisotumab vedotin is rapidly evolving. Active areas of investigation in 2L+ cervical cancer trials (2026):

• Novel ADCs targeting different tumor surface antigens
• CAR-T cell therapies targeting HPV E6/E7 oncoproteins (tumor-specific, unique to HPV-driven cancers — Phase 1 trials at NIH/NCI)
• Bispecific antibodies (anti-PD-1 + anti-CTLA-4, anti-LAG3, anti-TIGIT)
• mRNA-based therapeutic vaccines targeting HPV E6/E7
• Tumor-infiltrating lymphocyte (TIL) therapy
• PARP inhibitors for DNA repair-deficient subsets

How to find trials: ClinicalTrials.gov (search “cervical cancer” + filter: recruiting, interventional, phase 2–3); NCI Cancer Information Service 1-800-4-CANCER (free trial matching); GOG Foundation (gogfoundation.org); Foundation for Women’s Cancer (trial navigation).

• Pembrolizumab / Keytruda (Merck): Merck Access360: 1-855-257-3932
• Cemiplimab / Libtayo (Regeneron): Regeneron Oncology Patient Support: 1-877-542-8296
• Tisotumab vedotin / Tivdak (Pfizer): Pfizer RxPathways: 1-844-989-PATH (7284); Tivdak Together dedicated program
• Bevacizumab / Avastin (Genentech): Genentech Access Solutions: 1-888-249-4918. Multiple biosimilars (Mvasi, Zirabev, Alymsys) available at lower cost with same clinical efficacy.
• CancerCare Co-Pay Assistance Foundation: 1-866-55-COPAY
• NeedyMeds.org: Drug-specific patient assistance program database
• Livestrong Foundation: 855-220-7777; livestrong.org

• Given that I received pembrolizumab in first line, is cemiplimab likely to work for me?
• Am I a candidate for tisotumab vedotin? Can you arrange the required ophthalmology visits before starting?
• Has comprehensive genomic profiling (NGS) been ordered?
• Are clinical trials available for my specific situation at this center or nearby?
• Can I get a second opinion at a major gynecologic oncology center (MD Anderson, MSK, Mayo)?
• What symptoms from tisotumab vedotin should prompt me to call immediately?
• Is there a role for local treatment (palliative radiation, surgery) to control symptoms from specific metastatic sites?
• At what point should we have a goals-of-care conversation about the direction of treatment?
• Is there a palliative care specialist I should be seeing alongside my oncology team?

Invasive cervical cancer is an AIDS-defining malignancy. HIV-positive women have ~6-fold higher risk of cervical cancer due to impaired immune clearance of HPV, highest with low CD4 counts and detectable viral loads.

• Screening: Annual Pap smear for 3 consecutive years from HIV diagnosis, then every 3 years if normal. CD4 <200: many guidelines recommend continuing annual screening indefinitely.
• ART during cancer treatment: Drug-drug interactions between ART and chemotherapy must be evaluated by an HIV specialist. Cobicistat-boosted and ritonavir-containing regimens are potent CYP3A4 inhibitors that can alter chemotherapy pharmacokinetics significantly.
• Immunotherapy: Pembrolizumab can be used in HIV-positive patients on stable ART — experience is limited but manageable safety profile in trials including HIV-positive patients.
• Collaborative care: Requires close collaboration between gynecologic oncology, HIV/infectious disease, and palliative care. Many NCI-designated cancer centers have dedicated HIV malignancy programs.

Cervical cancer is the most common gynecologic cancer diagnosed during pregnancy (~1.5–12 per 100,000 deliveries). Management requires balancing maternal benefit against fetal risk.

• Imaging: MRI pelvis is preferred (avoids ionizing radiation). PET-CT generally avoided during pregnancy.
• Before viability (before ~22–24 weeks): For early-stage (IB1 or smaller), radical trachelectomy has been reported at highly specialized centers. For larger tumors, options include immediate treatment (radical hysterectomy with fetus in situ) or neoadjuvant chemotherapy to delay until viability.
• After viability (~22–24+ weeks): For early-stage disease with no evidence of rapid progression, careful surveillance (serial MRI every 4–6 weeks) to fetal viability, then delivery and definitive treatment.
• Brachytherapy: Absolutely contraindicated in pregnancy.
• Multidisciplinary team required: Gynecologic oncology, maternal-fetal medicine, neonatology, palliative care, and ethics consultation when relevant. Manage at comprehensive cancer centers with experience in this scenario.

Any person with a cervix requires cervical cancer screening on the same age-based schedule as cisgender women. HPV risk and cervical cancer risk are identical to cisgender women with respect to the cervix.

• Testosterone and Pap smears: Testosterone causes atrophic changes that complicate Pap interpretation. Notify the pathologist that specimens are from a testosterone-treated individual.
• Barriers to screening: Dysphoria related to gynecologic exams, discrimination, EHR gaps, and avoidance of care. Self-sampling HPV testing removes a major barrier.
• Cultural competency: Use correct pronouns and name; recognize that having a cervix does not define gender; minimize unnecessary genital exposure during examination.
• Resources: National LGBTQ Cancer Network; Human Rights Campaign; specialized LGBTQ+ oncology programs at UCSF, MSK, Dana-Farber.

Chronologic age alone is not a reliable indicator of treatment tolerance. A formal geriatric oncology assessment (G8 screening, comprehensive geriatric assessment, ECOG/Karnofsky performance status, ADL assessment, comorbidity index, polypharmacy review, nutritional status, cognitive assessment) should be performed before treatment planning for older patients.

Chemoradiation modifications: Carboplatin substitution for impaired renal function; reduced cisplatin dose (30 mg/m²) for those at high risk; radiation dose modification for poor bowel tolerance. For frail patients, a frank discussion about realistic treatment goals, quality of life priorities, and the burdens of intensive treatment (daily appointments for 6+ weeks) is essential.

• Central pelvic recurrence (no pelvic sidewall involvement, no distant metastases): Potentially salvageable. Pelvic exenteration may offer 40–60% cure rates in carefully selected patients. Multidisciplinary evaluation including GYN oncology, plastic/reconstructive surgery (vaginal reconstruction, urinary diversion), and colorectal surgery required.
• Pelvic sidewall recurrence: Generally not resectable with negative margins. May be amenable to palliative-intent SBRT for focal sites if prior radiation doses allow. Systemic therapy is primary approach.
• Para-aortic recurrence: Potentially treatable with SBRT or extended-field radiation if not previously irradiated. SBRT to oligometastatic para-aortic disease has shown promising results.
• Oligometastatic disease (1–3 sites): Local consolidation with SBRT to all metastatic sites while maintaining systemic therapy is being studied. Active area of investigation.
• Reirradiation: Possible at specialized centers using conformal techniques (SBRT, proton therapy) but carries significant late toxicity risk. Patient selection must be rigorous.

If you read about a cervical cancer treatment that isn't available where you live, it helps to know how access varies. The drugs that have most changed outcomes — pembrolizumab, bevacizumab, and tisotumab vedotin — are approved across the major regulators (US, Europe, Canada), but timing and coverage differ, and in some health systems you may need to try other treatments first before insurance funds a newer one. Where a specific drug is genuinely unavailable, ask your team about clinical trials of it, compassionate-use or expanded-access programs, and (where feasible) referral to a region or center where it is approved.

The more important global truth is about the curative backbone rather than the newest drugs. For locally advanced disease, the treatment that cures — chemoradiation with brachytherapy — depends on radiation infrastructure that is unevenly distributed: many regions lack adequate brachytherapy, and its absence substantially lowers cure rates. If you have locally advanced disease, confirming that your center offers brachytherapy (or arranging referral to one that does) is the single most important access question, more so than access to any individual drug.

Finally, the prevention tools — HPV vaccination and screening, including newer self-collection testing — are where access matters most at a population level, and where you can help beyond your own care by encouraging eligible family members to get vaccinated and screened. The same progress that can feel out of reach for the newest drug is, for prevention, increasingly within reach worldwide.

WHO targets for 2030 to eliminate cervical cancer as a public health problem: 90% of girls fully vaccinated with HPV vaccine by age 15; 70% of women screened with a high-performance test by age 35 and again by age 45; 90% of those identified with cervical disease receiving treatment.

Current global HPV vaccination coverage lags in sub-Saharan Africa (<20% in many nations) and South Asia. Several Latin American nations have achieved 70–80% via national programs. PAHO coordinates regional efforts across Latin America and the Caribbean.

• Australia: Shifted from Pap smear to HPV-primary screening in 2017, a world-leading model. On track to be first country to meet WHO elimination threshold. Peter MacCallum Cancer Centre (Melbourne) is the national gynecologic oncology referral center.
• UK: NHS-funded Gardasil 9 vaccination for ages 12–13 via national school program. Christie Hospital (Manchester) and Royal Marsden (London) are leading cervical cancer centres.
• Japan: HPV vaccination controversy (2013 national recommendation suspension) caused coverage gaps and cervical cancer incidence rose as a result; vaccination reinstated 2022. PMDA approved pembrolizumab for cervical cancer 2022.
• India: Cisplatin + EBRT + brachytherapy is the standard of care. TATA Memorial Hospital (Mumbai) is the national referral center. Biosimilar bevacizumab (Bevatas, Biocon) widely used. Pembrolizumab access limited to private hospitals.
• China: Sintilimab (Innovent Biologics) approved in China for squamous cell cervical cancer in combination regimens. Not available in Western markets. Major centers include Peking Union Medical College Hospital and Sun Yat-sen University Cancer Center.
• Africa: SAHPRA oversees approvals in South Africa. Sub-Saharan Africa carries the highest global cervical cancer burden. WHO/UICC programs work to expand radiotherapy access.

What was tried: Laparoscopic and robotic radical hysterectomy were widely adopted in the 2000s–2010s for early-stage cervical cancer based on smaller incisions and faster recovery.

Why it failed (LACC trial, NEJM 2018, NCT00614211): DFS 91.2% (MIS) vs 97.1% (open) at 4.5 years; OS significantly worse for MIS (HR 6.00 for MIS-related death). Trial stopped early by DSMB for unequivocal MIS inferiority. A concurrent SEER-Medicare retrospective analysis confirmed real-world mortality rise paralleling MIS adoption.

Current standard: Open abdominal radical hysterectomy (NCCN Category 1). MIS should not be offered outside of carefully designed protocols for the narrowest indications (≤2 cm, no LVSI, specialized center, full informed consent).

Both erlotinib and cetuximab were tested in cervical cancer based on EGFR overexpression in squamous cell carcinomas. Neither showed meaningful single-agent activity in Phase 2 trials. Unlike head-and-neck SCC, cervical cancer does not harbor EGFR-activating mutations. Neither is used in cervical cancer.

• Aflibercept (Zaltrap): Phase 2 trials showed insufficient single-agent activity. Did not advance to Phase 3.
• Nintedanib (Ofev): Failed in Phase 2 with insufficient response rates and high toxicity burden.
• Sunitinib (Sutent): Minimal activity as monotherapy in Phase 2. Did not advance.

GOG-0240 tested topotecan+paclitaxel as a platinum-free option for patients with prior cisplatin exposure. It was not superior to cisplatin+paclitaxel in overall survival and has more hematologic toxicity. It is no longer preferred as first-line backbone. Occasionally used when cisplatin is definitively contraindicated and carboplatin is also not possible.

The CALLA trial (NCT03830866) tested durvalumab (anti-PD-L1) added to chemoradiation for locally advanced cervical cancer. Primary endpoint (PFS) was not met (HR 0.84, p=0.07). This confirms that anti-PD-L1 (durvalumab) and anti-PD-1 (pembrolizumab) are not interchangeable — only pembrolizumab (KEYNOTE-A18) is FDA-approved with chemoRT for locally advanced cervical cancer.

PARP inhibitors (olaparib, niraparib, rucaparib) — transformative in BRCA-mutated ovarian, breast, and prostate cancers — have not found a role in cervical cancer. Cervical cancer is driven by HPV integration, not BRCA/HRD defects. PARP inhibitors are not used outside of genomically selected clinical trial settings.

Multiple therapeutic vaccine approaches targeted HPV E6/E7: VGX-3100 (Inovio, DNA vaccine) showed some histologic regression in CIN2/3 in Phase 3 but did not achieve FDA approval. Tipapkinogen sovacivec (TA-HPV) also failed in Phase 3. However, HPV E6/E7-targeting CAR-T cells (under investigation at NIH) represent a distinct and more potent approach — cellular therapy, not a vaccine.

The FIGO 2009 staging system was based purely on clinical examination and did not incorporate lymph node status or imaging findings. This led to under-staging of many patients with pelvic or para-aortic lymph node metastases. FIGO 2018 revised staging incorporates LN status (r=imaging, p=pathologic), providing more accurate prognostic grouping and treatment planning. FIGO 2009 should no longer be used for treatment planning.

Cervical cancer treatment affects the body in ways that touch sexuality and intimacy directly, yet this is one of the least-discussed parts of survivorship — often because both patients and clinicians find it awkward to raise. Naming it plainly helps: surgery and especially radiation can cause vaginal dryness, narrowing or shortening (stenosis), reduced sensation, and, if the ovaries were affected, the symptoms of menopause. These are common, expected effects of treatment, not something you have done wrong or must simply accept in silence.

Much can be done. Regular use of a vaginal dilator after radiation, along with vaginal moisturizers and lubricants, substantially reduces stenosis and keeps intimacy and future pelvic exams comfortable — starting it on the schedule your team recommends (usually a few weeks after treatment) matters. For menopausal symptoms after the ovaries are affected, hormone therapy is often safe in cervical cancer (which is not hormone-driven) and worth asking about. Pelvic-floor physical therapy, counseling, and referral to a sexual-health or survivorship specialist are real, effective resources — not luxuries.

The emotional dimension matters as much as the physical. Changes in body image, fear of recurrence, the strain on a partnership, and grief over fertility can all affect intimacy, and they respond to support — whether from a counselor, a support group of other survivors, or open conversation with a partner. The single most useful step is to give yourself permission to raise these issues with your care team; they are a routine and important part of recovery, and bringing them up is what unlocks the help that exists.

Finishing treatment brings relief but also a new kind of anxiety — the fear that the cancer could come back — and understanding the follow-up plan helps make that fear more manageable. Most recurrences, if they happen, occur in the first two to three years, so follow-up visits are more frequent early on (often every three to six months) and then space out. These visits center on talking with you and a physical and pelvic exam rather than routine scans, because for people without symptoms, frequent scans have not been shown to help and mainly add cost and worry. Your team will image or test when something specific prompts it.

You are an essential part of this surveillance. Learn the symptoms worth reporting promptly rather than waiting for the next appointment: new or persistent pelvic or low-back pain, swelling of one leg, unusual vaginal bleeding or discharge, or new problems with urination or bowels. Reporting these early matters because a recurrence caught while it is still confined to the pelvis can sometimes still be treated with the goal of cure.

Beyond watching for recurrence, ask your team for a survivorship plan that addresses the lasting effects of treatment — vaginal and sexual health, leg swelling (lymphedema), bladder and bowel changes, menopause symptoms, and emotional wellbeing. These are common and treatable, and naming them in a plan makes sure they don't get lost once active treatment ends. Survivorship is its own phase of care, and you deserve attention to living well, not just to scan results.

• Vaginal dilators: Graduated plastic or silicone dilators prescribed by the care team. A pelvic floor PT can guide proper technique. Many hospitals provide a starter kit at the end of radiation.
• Vaginal lubricants and moisturizers: Water-based or silicone-based lubricants for sexual activity. Long-acting vaginal moisturizers (e.g., Replens) used regularly maintain vaginal tissue health.
• Topical vaginal estrogen: Safe after cervical cancer (not hormone-driven). Low-dose vaginal estrogen (cream, ring, tablet) reduces dryness and improves tissue integrity.
• Pelvic floor physical therapy: Addresses vaginismus, pelvic pain, bladder urgency, and bowel dysfunction. Referral should be routine after pelvic radiation or radical hysterectomy.
• Libido and psychological factors: Hormonal changes from premature menopause, body image changes, fear of recurrence, depression, and anxiety all affect sexual desire. Psychological counseling and sex therapy are effective. Systemic HRT can help with libido.

Lower extremity lymphedema affects 10–40% of women after cervical cancer treatment. It is a chronic condition requiring active management, not a temporary swelling that will resolve on its own.

• Compression garments: Prescription gradient compression stockings (Class 2–3). Fit by a certified lymphedema therapist.
• Manual lymphatic drainage (MLD): Specialized massage technique redirecting lymph flow through alternative pathways. Most effective when started early after lymphadenectomy.
• Exercise: Aquatic exercise, walking, and lymphedema-specific programs help pump lymph fluid. Avoid tight clothing, prolonged standing, hot tubs (heat worsens swelling).
• Skin care: Keep skin moisturized. Any break in skin (cuts, insect bites) in the affected leg is a portal for cellulitis — serious in lymphedematous limbs.
• Identify early: Any new persistent leg swelling, heaviness, or tightness after cervical cancer surgery should be evaluated promptly. Early lymphedema is much easier to manage.

Acute radiation-induced diarrhea: Low-residue, low-fat diet; loperamide or bismuth subsalicylate as directed; adequate hydration; avoid dairy if lactose-intolerant. Report blood in stool immediately.

Chronic radiation proctitis: Rectal urgency, loose stools, rectal bleeding. Managed with sucralfate enemas, short-chain fatty acid enemas, hyperbaric oxygen therapy (HBOT) for refractory cases, argon plasma coagulation (APC) for radiation telangiectasias. Referral to colorectal specialist or radiation enteritis clinic recommended.

Bladder management: Urgency/frequency/dysuria from radiation cystitis managed with phenazopyridine, anticholinergics (oxybutynin, tolterodine), avoiding caffeine/alcohol. Any hematuria (blood in urine) months to years after radiation requires evaluation (cystoscopy) to rule out recurrence. HBOT has evidence for radiation-induced hemorrhagic cystitis.

Surgical menopause (bilateral oophorectomy) or radiation-induced ovarian failure causes abrupt estrogen withdrawal in premenopausal women, with more severe symptoms than natural menopause.

• HRT: Strongly recommended and considered safe for cervical cancer survivors. Reduces vasomotor symptoms, vaginal atrophy, bone loss, and cardiovascular risk.
• Hot flash alternatives: SSRIs/SNRIs (venlafaxine, escitalopram), gabapentin. Acupuncture has modest evidence.
• Bone health: DEXA scan baseline. Calcium 1200 mg/day + Vitamin D 1000–2000 IU/day. Bisphosphonate therapy if osteoporosis confirmed.

• Cervical cancer stigma: The HPV connection sometimes causes stigma or self-blame — medically unwarranted. HPV exposure is nearly universal; cervical cancer is not a personal failing. Cervivor (cervivor.org) is a peer-led advocacy community specifically addressing HPV-related cancer stigma.
• SHARE Cancer Support: 1-866-891-2392 | Free peer support groups for GYN cancer survivors; Spanish-language programs available
• Foundation for Women’s Cancer: foundationforwomenscancer.org | Resources and support for all gynecologic cancer types
• CancerCare: 1-800-813-4673 | Free counseling, support groups, limited financial grants
• PHQ-9 and GAD-7 screening: Should be routine at oncology visits. Untreated depression reduces treatment adherence and quality of life.

• Radical trachelectomy: For selected IB1 patients (≤2 cm, node-negative, squamous histology). Removes the cervix while preserving the uterus. Pregnancy is possible afterward. Established programs at HCI, Mayo, MSK, and MD Anderson.
• Egg/embryo freezing: Oocyte or embryo cryopreservation before starting treatment. Typically requires 2–3 weeks. Oncofertility programs coordinate fertility specialists with oncology.
• Ovarian transposition (oophoropexy): Before pelvic radiation, ovaries moved outside the radiation field. Preserves natural hormone production. Success rate 50–80% (radiation scatter may still cause premature ovarian failure).
• Surrogacy and adoption: For women not candidates for fertility-sparing surgery, gestational surrogacy (using frozen embryos) and adoption are pathways to parenthood.

• Immunotherapy toxicity surveillance (pembrolizumab, cemiplimab): Report any new rash, diarrhea >3x/day over baseline, shortness of breath, joint pain, visual changes, or any new neurological symptom. irAEs can occur weeks to months after the last infusion.
• Tisotumab vedotin eye care at home: Cool compresses, steroid eye drops, and lubricating drops required before, during, and after each infusion cycle. Ophthalmology every 6 weeks. Report any eye pain, redness, vision change, or photophobia immediately.
• Nutrition during chemoradiation: High-calorie, high-protein foods (eggs, Greek yogurt, protein shakes, nut butters) maintain weight and treatment tolerance. Low-residue diet during radiation. Refer to an oncology dietitian before treatment begins.
• Medication management: A simple calendar with times, doses, and refill dates for all supportive medications (anti-emetics, growth factors, corticosteroids) reduces missed doses and errors.
• For pelvic exenteration patients: The patient will live with an ostomy bag for urine and/or feces. Stoma nurse education before and after surgery; complete decongestive therapy for lymphedema; emotional support for body image changes. CancerCare 1-800-813-4673 offers support groups for GYN cancer survivors with ostomies.

Adenocarcinoma

A type of cervical cancer arising from gland cells lining the endocervical canal. Accounts for ~25% of cervical cancers. HPV 18 is the predominant driver. Harder to detect on standard Pap smear than squamous cell carcinoma.

Adjuvant chemoradiation

Radiation therapy (external beam) plus concurrent cisplatin given after radical hysterectomy when high-risk features are found on pathology (Peters criteria: positive surgical margins, positive pelvic lymph nodes, or parametrial invasion).

Bevacizumab (Avastin)

An anti-VEGF monoclonal antibody that blocks tumor blood vessel formation. FDA approved 2014 for recurrent/metastatic cervical cancer in combination with chemotherapy (GOG-0240). Manufactured by Genentech/Roche. Key risks: hypertension, proteinuria, fistula (vesicovaginal or rectovaginal), impaired wound healing, GI perforation.

Brachytherapy

Internal radiation therapy placing a radioactive source directly inside or near the tumor. A mandatory component of curative-intent treatment for cervical cancer. Modern standard is image-guided adaptive brachytherapy (IGABT) using MRI guidance to optimize dose to tumor while sparing bladder, rectum, and bowel.

Cemiplimab (Libtayo)

A PD-1 checkpoint inhibitor (Regeneron/Sanofi). FDA approved Sept 2021 for 2L+ recurrent/metastatic cervical cancer, regardless of PD-L1 expression level. Given as 350 mg IV every 3 weeks.

CIN (Cervical Intraepithelial Neoplasia)

Precancerous changes in cervical cells, graded 1 (mild), 2 (moderate), or 3 (severe/CIS). CIN1 often regresses spontaneously. CIN2/3 treated with LEEP or cold knife cone biopsy to prevent progression to invasive cervical cancer.

Cisplatin

Platinum-based chemotherapy; the backbone of concurrent chemoradiation for cervical cancer (40 mg/m² weekly during radiation) and the preferred partner in the metastatic setting. Side effects: kidney toxicity, peripheral neuropathy, nausea, hearing loss. Requires pre-hydration.

Colposcopy

Magnified examination of the cervix after an abnormal Pap or positive HPV test. Acetic acid and Lugol’s iodine applied to highlight abnormal areas. Biopsies taken from suspicious sites to diagnose CIN or invasive cancer.

CPS (Combined Positive Score)

Measure of PD-L1 expression: (PD-L1-staining cells [tumor + immune] / total viable tumor cells) × 100. Threshold of 1 for pembrolizumab benefit in cervical cancer (KEYNOTE-826) — approximately 85–90% of cervical cancers qualify. Requires Dako 22C3 assay specifically.

FIGO Staging

International Federation of Gynecology and Obstetrics staging system for cervical cancer. Updated 2018 to incorporate lymph node status (r=radiologic, p=pathologic). Stages IA1 through IVB.

HPV (Human Papillomavirus)

Sexually transmitted virus responsible for >99% of cervical cancers. High-risk subtypes (especially HPV 16 and 18) cause cancer by integrating into the host genome and producing E6/E7 oncoproteins that inactivate p53 and Rb. Gardasil 9 (Merck) prevents infection with HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58 — covering strains responsible for ~90% of cervical cancers.

IGBT / IGABT (Image-Guided [Adaptive] Brachytherapy)

Brachytherapy planned and delivered using real-time MRI or CT imaging to precisely target the tumor and spare adjacent organs. GEC-ESTRO and ABS guidelines define the modern standard. Dramatically lower local recurrence rates and late toxicity vs older 2D methods. Available at HCI, MD Anderson, MSK, and other major centers.

IMRT (Intensity-Modulated Radiation Therapy)

External beam radiation that modulates beam intensity to conform the high-dose zone to the tumor while sparing surrounding normal structures. Reduces grade 3+ GI and GU toxicity by 30–50% vs 3D-CRT without compromising tumor control. Standard at most comprehensive cancer centers.

LACC Trial

Landmark randomized Phase 3 trial (NCT00614211, NEJM 2018) proving minimally invasive radical hysterectomy is inferior to open abdominal surgery for early-stage cervical cancer (worse DFS and OS). Open surgery re-established as the standard.

LEEP (Loop Electrosurgical Excision Procedure)

Outpatient surgical procedure using a wire loop to remove abnormal cervical tissue (CIN2/3 or microinvasive IA1). Provides treatment and a pathology specimen. Alternative: cold knife conization (CKC) in OR when larger margins needed or invasive cancer suspected.

Lymphedema

Chronic leg swelling from disrupted lymphatic drainage after pelvic lymph node dissection. Affects 10–40% after cervical cancer treatment. Requires active long-term management: compression garments, MLD massage, exercise, skin care.

MSI-H / MMR Deficiency

Microsatellite instability-high / mismatch repair deficiency — biomarkers of DNA repair dysfunction. Rare in cervical cancer (~1–3%) but confer FDA tumor-agnostic pembrolizumab eligibility regardless of CPS or prior lines of therapy.

Neuroendocrine Cervical Carcinoma

Rare (<2%) but aggressive histologic subtype. Small cell neuroendocrine carcinoma (SCNEC) behaves like small cell lung cancer: early systemic spread, paraneoplastic syndromes possible. Treated with etoposide+cisplatin. Requires specialized management at high-volume centers.

Pembrolizumab (Keytruda)

PD-1 checkpoint inhibitor (Merck). FDA approved Oct 2021 for 1L recurrent/persistent/metastatic cervical cancer (CPS≥1 and all-comers) + chemo ± bev (KEYNOTE-826); FDA approved Jan 2024 for locally advanced cervical cancer + chemoRT (KEYNOTE-A18). Given as 200 mg IV q3wks.

Pelvic Exenteration

Extensive surgery removing the uterus, cervix, vagina, and adjacent pelvic organs (bladder and/or rectum) for centrally recurrent cervical cancer after prior radiation. Potentially curative (5-year OS 40–60% in selected cases). Performed only at high-volume centers by experienced surgeons.

Radical Hysterectomy

Surgical removal of the uterus, cervix, upper vagina, and parametria, plus bilateral pelvic lymph node dissection. Classified by Querleu-Morrow criteria: Type B (modified radical, partial parametrectomy); Type C1 (nerve-sparing, full parametrectomy); Type C2 (non-nerve-sparing). Open (abdominal) approach is the standard per LACC trial.

Sentinel Lymph Node (SLN) Biopsy

Identifies the first lymph node(s) draining the cervix using ICG fluorescence and/or technetium. Bilateral detection required. Ultrastaging detects micrometastases and isolated tumor cells. Validated by SENTICOL and SENTIX trials for early-stage cervical cancer (≤2 cm). Substantially reduces lymphedema risk vs full lymphadenectomy.

Tissue Factor (TF)

Cell surface protein overexpressed on ~90% of cervical cancer cells. Target of tisotumab vedotin (Tivdak). TF expression testing not required before prescribing tisotumab vedotin.

Tisotumab Vedotin (Tivdak)

Antibody-drug conjugate (ADC) targeting TF, delivering MMAE payload to tumor cells (Seagen/Pfizer). Full FDA approval for 2L+ recurrent/metastatic cervical cancer after platinum and anti-PD-1/PD-L1 therapy. Mandatory ocular toxicity prevention protocol required at each infusion.

Trachelectomy (Radical)

Fertility-sparing surgery removing the cervix and upper vagina while preserving the uterine body. For selected IB1 patients (≤2 cm, node-negative, squamous histology). Allows future pregnancy but carries risk of preterm labor and cervical incompetence.

Vaginal Stenosis

Narrowing and shortening of the vaginal canal from radiation fibrosis. Very common after pelvic radiation + brachytherapy. Largely preventable with consistent vaginal dilator use beginning 2–3 weeks after completing brachytherapy, 3 times per week, continued long-term.